Abbvie Inc.

Abbott Laboratories Corporation

Abbott Molecular Inc.

Dimitri Semizarov

Xin Lu

Rick R Lesniewski

Ke Zhang

John S Coon

Ekaterina Pestova

Christin Tse

Richard R Lesniewski

David Ching Siang Huang

Mark F Van Delft

Lloyd T Lam

Mona Stein Legator

Tamar Uziel

Jameel Shah

Mark Anderson

Jun Guo

The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.

Diagnostic methods for determining prognosis of non-small cell lung cancer

The methods and compositions described herein address the need for a diagnostic method that can be provided to patients with early stage lung cancer, especially non-small cell lung cancer (NSCLC), to determine whether the patient is at increased risk of poor disease outcome. The methods and compositions thus allow for more informed treatment decisions for the early stage lung cancer patient.

Detection of chromosomal abnormalities associated with prognosis of non small cell lung cancer

Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus.

The invention is directed to methods and kits that allow for identifying, classifying, and monitoring cancer patients for Bcl-2 family inhibitor therapies. The methods and compositions of the invention are directed to determining amplification of Bcl-xand in cancer or tumor cells, or elevated Bcl-xpolypeptide expression.

Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers

The present invention relates to algorithms for use in defining genomic subgroups of tumors and cancer cell lines. The present invention also relates to methods for assembling panels of tumors and cancer cell lines according to genomic subgroups for use in testing the efficacy of one or more pharmaceutical compounds in the treatment of subjects suffering from at least one cancer.

Methods for assembling panels of cancer cell lines for use in testing the efficacy of one or more pharmaceutical compositions

MicroRNAs (miRNAs) that sensitize cancer cells to Bcl-2 family protein inhibitors are identified and described. Oligonucleotide panels, arrays and methods using the sensitizing miRNAs are also disclosed.

Panel of micrornas that silence the MCL-1 gene and sensitize cancer cells to ABT-263

The invention is directed to methods and kits that allow for classification of colorectal cancer cells according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same.

Genomic classification of colorectal cancer based on patterns of gene copy number alterations

The invention is directed to methods and kits that allow for classification of malignant melanoma cells according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same.

Genomic classification of malignant melanoma based on patterns of gene copy number alterations

The invention is directed to methods and kits that allow for classification of non-small cell lung carcinoma tumors and cell lines according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same.

Growing community of inventors

Chicago, IL, United States of America

Dimitri Semizarov